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The Bipolar Mood Disorder is characterized by the alternation of depressive crises with episodes of mania 
or euphoria, having these patients 15 to 35 times more chances of suicide, as compared with people without 
this disorder. The pharmacotherapy is fundamental for this disease, aiming to decrease the frequency 
of episodes and disease severity. In these patients, the polypharmacy has recently increased and one of 
the main difficulties is the adherence to treatment. The objective of this study was to contribute for the 
improvement of bipolar patients health conditions, developing their respective pharmacotherapeutic 
follow-up. Twenty eight adult bipolar patients who were participants of a specialized clinic within a tertiary 
hospital in Porto Alegre have been randomly selected, and the Dader Method of pharmacotherapeutic 
follow-up has been applied. The more common clinical comorbidities were: hypertension (50%), 
obesity (46.43%), and hypothyroidism (36.29%). The bipolar patients are more susceptible to clinical 
comorbidities, and many of them could be due to pharmacotherapy. Only 1.43% of patients presented 
Drug Related Problems, being all of them resolved along the study. It was also observed that 32.14% 
of evaluated patients presented low adherence to treatment, and between these patients, 55.56% passed 
to have good adherence after pharmacotherapeutic follow-up. The pharmacotherapeutic follow-up 
is fundamental for the improvement of patient’s health. New studies, with higher number of patients 
and longer duration, are necessary to evaluate the percentage of patients that could be beneficiary of 
Pharmaceutical Care.
Uniterms: Pharmaceutical Care. Bipolar Mood Disorder. Pharmacotherapy.
O Transtorno do Humor Bipolar é caracterizando pela alternância de crises depressivas com episódios 
de mania ou euforia, tendo estes pacientes 15-35 vezes mais chances de suicídio em comparação com 
pessoas sem este transtorno. A farmacoterapia é fundamental, visando diminuir a freqüência dos episódios 
e a gravidade da doença. Nestes pacientes, a polifarmácia tem aumentado ultimamente e uma das maiores 
dificuldades é a adesão ao tratamento. O objetivo do estudo foi contribuir para a melhoria das condições 
de saúde de pacientes bipolares, realizando o acompanhamento farmacoterapêutico dos mesmos. 
Foram selecionados aleatoriamente 28 pacientes bipolares adultos, participantes de um ambulatório 
especializado de um hospital terciário em Porto Alegre e aplicado o Método Dáder de acompanhamento 
farmacoterapêutico. As co-morbidades clínicas mais comuns foram: hipertensão (50%), obesidade 
(46,43%) e hipotiroidismo (39,29%). Os pacientes bipolares são mais suscetíveis a co-morbidades 
clínicas e muitas destas podem ser devidas a farmacoterapia. Apenas 1,43% dos pacientes apresentavam 
Problemas Relacionados a Medicamentos, sendo todos solucionados no decorrer do estudo. Também se 
observou que 32,14% dos pacientes avaliados apresentavam baixa adesão ao tratamento e entre estes, 
55,56% passaram a ter boa adesão após o acompanhamento farmacoterapêutico. É fundamental para 
a melhoria da saúde do paciente o acompanhamento farmacoterapêutico. Novos estudos, com maior 
número de pacientes e maior duração, são necessários para avaliar o percentual de pacientes que poderão 
ser beneficiados pela Atenção Farmacêutica.
Unitermos: Atenção farmacêutica. Transtorno do Humor Bipolar. Farmacoterapia.
K. M. M. Ceresér, M. A. Mascarenhas, A. Santin, F. Kapczinski250
INTRODUCTION
The utilization of medications is a complex process, 
with many determinants, and the adequate pharmacothera-
peutic guidelines for the clinical condition of an individual 
are essential elements for the determination of medications 
employment. However, it is important to remember that 
the prescription and use of medications are influenced by 
factors of cultural, social, economical and political nature 
(Perini et al., 1999; Faus, 2000).
The morbimortality related to medications is a rele-
vant public health problem and a determinant of hospital 
internments, which could be attributed to drug activity, 
therapeutic failures, non-adherence to treatment, and 
adverse events (Johnson, Bootman, 1995; Easton et al., 
1988; Roughead et al., 1998; Malhotra et al., 2001). The 
traditional models of pharmaceutical practice have shown 
little effectiveness respecting to morbimortality related 
to medications (Cipolle et al., 2000). The prevalence and 
costs of morbimortality related to medications are relevant 
for the health systems managers, patients and society as a 
whole (Johnson, Bootman, 1995; Malhotra et al., 2001).
The main causes of preventable morbidity related 
to medications are: inadequate prescription, unexpected 
adverse reactions to medications, non-adherence to treat-
ment, overdose or subdose, lack of necessary pharmaco-
therapy, inadequate follow-up of signals and symptoms, 
and medication errors (Hennessy, 2000; Hepler, 2000). 
According Hepler (2000), the preventable morbi-
dity related to medications must be controlled through 
the following strategies: a) increase of population and 
health professionals conscience about the problem; b) 
development and dissemination of control strategies for 
the health programs; c) identification and determination of 
problems relationship involving medication utilization in 
the population; d) provision of means to resolve or avoid 
the evolution of problems; e) improvement of medications 
utilization criteria.
The Pharmaceutical Care (PC) is an alternative that 
looks to improve the process quality of medications utili-
zation, reaching positive results. Roughead et al. (1998) 
published a review in which they demonstrate that rates of 
hospital internments related to medications corresponded 
to 2-4% of total hospital internments, 6-7% of emergency 
admissions, 12% of admissions in medical clinic units, 
and 15-22% of admissions in emergencies of geriatrics.
In 2002, Winterstein et al. published a metanalysis 
respecting hospital internments related to medications, 
demonstrating that their prevalence could vary between 
3-9% of hospital internments, and a percentage over 50% 
of such internments could be prevented.
The quality of life improvement in patients with 
cardiac failure, diabetes, hypertension, and dyslipidemia, 
occurring as a consequence of Pharmaceutical Care, was 
demonstrated by Jaber et al. (1996). Hepler (2000) has also 
developed a project to evaluate Pharmaceutical Care in 
asthmatic patients; in Europe, works showing the positive 
impact of Pharmaceutical Care in asthma have also been 
developed (Gourley et al., 1998; Hepler, 2000). Kaboli et 
al. (2006) published a systematic review, describing posi-
tive findings referring to activities of clinical pharmacists 
working within hospital teams. 
The practice of PC requires the pharmacist coope-
rating with the patient and other healthcare professionals, 
having as his main role the identification of existing or 
potential Drug Related Problems (DRP) and, respectively, 
their resolution or prevention (Hepler, Strand, 1990; He-
pler, 1993; OMS, 1993; Kaboli et al., 2006). 
According to the committee of the Second Con-
sensus of Granada on Drug Therapy Problems (2002), 
the DRP could be classified into three groups: necessity 
problems (when the patient makes use of an unnecessary 
medication, or when he/she does not utilize a necessary 
medication); effectiveness problems (when the utilized 
medication does not promote the desired effect, being it 
or not a dose-dependent result); safety problems (when the 
patient utilizes a medication that is not being safe, either 
due to utilization of a very high dose, or thanks to appea-
rance of adverse reactions, irrespectively of utilized dose).
A study developed by Crockett et al. (2006), sug-
gests that the pharmacist’s involvement could be beneficial 
to treatment of patients with unipolar depression. There 
are no specific works describing the pharmaceutical orien-
tation to bipolar patients.
The Bipolar Mood Disorder (BMD) is a chronic 
and recurrent disease affecting 1-5% of population. It is 
characterized by the alternation of depressive crises with 
episodes of mania or euphoria and it is classified into two 
categories: Type I disorders and Type II disorders. The 
Type I BMD presents an entire amplitude of mood varia-
tion, from the higher peak (full mania), which could last 
for several weeks, up to severe depressions. Generally, it 
starts in the age range between 15 and 30 years, and com-
monly presents psychotic symptoms or hallucinations. In 
the Type II BMD, the maniac phase is gentler and short, 
being called hypomania and the depressions could be 
deeper. They could start in the adolescence, with mood os-
cillation, but a part of patients only express the depressive 
phase around the age of 40 years. Frequently, the mood 
symptoms lay aside their pronounced nature of a single 
pole, to exhibit mixed characteristics (DSM-IV TR, 2000).
The bipolar patients are of difficult diagnosis, mainly 
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in the initial course of their disease, because they could 
present only depressive symptoms and manifest a maniac 
episode only after years. The diagnosis veracity is deter-
minant for the effectiveness of pharmacologic treatment 
(Schou, 1999; Keck, 2003; Gazalle et al., 2005). The bi-
polar disorders are common and recurrent, bringing huge 
socio-economic damages to patients and society, such 
as absenteeism and excessive expenses. Besides, these 
patients present 15 to 35 times more chances of suicide, 
as compared with people without this disorder (Burgess 
et al., 2002).
In view of disease severity, the pharmacologic treat-
ment is fundamental and aims to decrease the frequency of 
episodes, the disease severity, and improve the psycho-so-
cial consequences (Guscott, Taylor, 1994; Sproule, 2002). 
The concomitant use of several drugs for the treatment of 
BMD has increased in the late years (Gazalle et al., 2007), 
and one of the major difficulties in the treatment of these 
patients is the adherence to treatment. It was developed a 
review respecting treatment adherence in bipolar patients 
(Santin et al., 2005), where factors linked to medications 
(undesired effects, drug interactions, complex regimen), 
factors linked to patient (cognitive alterations, knowledge 
about the disease, personality), and factors linked to phy-
sician (interaction with patients) were verified as possible 
cause for the low adherence.
The lithium is the mood stabilizer of choice for the 
treatment of bipolar patients, because it is effective in the 
acute crises and along treatment maintenance, besides to 
be the single drug with anti-suicide action (Schou, 1999).
The individuals bearing BMD have their everyday 
significantly affected in a negative way, to the point of 
damage their social and professional interrelationships; 
such problems could be softened, and in some cases 
even cured, when these individuals follow correctly the 
prescribed therapeutic plan (Iñesta, 2000). This affirma-
tion reinforces the importance of a pharmacotherapeutic 
follow-up developed by a pharmacist professional, who 
shall monitor the therapeutic regimen and, if necessary, 
jointly with the physician, review the regimen respecting 
the progresses, positive results reaching, and treatment 
effectiveness (Iñesta, 2000). 
Another positive point of PC, when applied to 
psychiatric disorders, is the education of patients, their 
relatives, and coexisting people (Juruena, Vieira, Busnello, 
2000). The education is an essential component of the 
combined treatment of BMD, as several clinical studies 
have already demonstrated. The psycho-social interven-
tion during the maintenance treatment has been recognized 
as an important tool to stimulate treatment adherence, in 
patients with BMD (APA, 2002). 
The successfully tested psychological interventions 
contemplate classical psycho-educative elements, such as 
to improve the insight respecting the disease, to deal with 
stigmatization, to improve treatment adherence, and to 
teach the patient and his family to identify early prodromal 
signals, to promote healthy habits and the lifestyle regu-
larity, and avoid substances abuse (Colom, Vieta, 2004).
The Pharmaceutical Care is a model of professional 
practice developed by the pharmacist, in which this pro-
fessional jointly with the remaining members of the health 
team, identifies, evaluates, and look to resolve the DRP.
The objective of this study was to contribute for 
the improvement of health conditions of bipolar patients, 
developing their respective pharmacotherapeutic follow-
up. This work is part of a research project that count on 
the support of CNPq, in the pharmaceutical care area, and 
it was developed between 2006 January and 2007 June.
METHODS
Twenty eight adult patients were randomly selected 
(21 women and 07 men), bearers of Bipolar Mood Disor-
der (BMD), participants of the Bipolar Mood Disorder 
Program from the Hospital of Clinics of Porto Alegre 
(Programa de Transtorno do Humor Bipolar do Hospital 
de Clínicas de Porto Alegre – PROTAHBI-HCPA). The 
distribution of the investigated sample respecting to gen-
der was the same as that in the studied population.
It was applied the Dader Method of pharmaceu-
tical follow-up, developed by the Pharmaceutical Care 
investigation group of the University of Granada, in 1999 
(Machuca, Fernández-Llimós, Faus, 2003, Dader, Muñoz, 
Martinez-Martinez, 2008). According this methodology, 
the pharmacotherapeutic follow-up is composed by the 
following steps: first interview, situation status, study and 
evaluation phase, intervention, interventions results, and 
new situation status.
Before the first interview, every patient was con-
tacted, personally or by phone, when it was explained the 
methodology and scheduled the first interview, occasion in 
which the patient should bring a bag with all medications 
utilized by him, including those used only occasionally or 
by self-medication.
The first interview was developed in a place in 
which the patient felt himself at ease; when he exposed 
his current and previous health problems, without any 
intervention from the pharmacist. In a second moment of 
this interview, the pharmacist evaluated some of the infor-
mation provided by the patient, requesting more detail as 
well as fulfilling a detailed card respecting his currently 
used medications, in which, for every medication taken, 
K. M. M. Ceresér, M. A. Mascarenhas, A. Santin, F. Kapczinski252
the patient should answer: who prescribed it, for what re-
ason, if he was feeling better, since when he was utilizing 
it, how much medication was he using per day, how was 
he using it, until when should he utilize it, and if he was 
feeling something strange or some difficulty related to 
that medication.
The pharmacist observed and noted details respec-
ting the patient’s knowledge about the medication and 
respecting his adherence to it. The patient was also asked 
respecting the previously used medications, and the reason 
for their suspension.
To finish this first interview, the pharmacist did a 
revision, relating all body parts, letting the patient report 
the problems found. He also asked about the patient’s lifes-
tyle, as alcohol consumption, smoking habits, drugs use, 
nurture habits; coffee, teas or “mate” consumption, and se-
dentarism. This first interview had an average duration of 
two hours, occasion in which it were also applied scales for 
evaluation of probable depression or mania, respectively 
Hamilton Depression (HAM-D) and Young Mania Rating 
Scale (YMRS), being also checked the weight, height, and 
signed the ‘Informed Consent Form’ (ICF). It was consi-
dered as maniac or depressed the patient presenting scores 
higher or equal to 7, respectively, in the scales HAM-D 
and YMRS. The individuals totalizing scores lower than 
7 in both scales, were considered as euthymic.
After the first interview, it was elaborated the 
patient’s first situation status, in which were described 
the probable relationships between health problems and 
medications.
In the following phase of studies and evaluation, it 
was developed a consultation in the patient’s history and 
a talk with his personal psychiatrists occurred, besides a 
search by the investigators, for explanations to possible 
DRP in the medical literature.
In the intervention phase (normally, one month after 
the initial interview), firstly the evaluation results were 
presented to the clinical team, in order to develop the ne-
cessary interventions. It was then scheduled a second phar-
maceutical consultation, in which the patient was clarified 
about DRP and received orientation about the rational use 
of medications and improvement of his lifestyle.
During the intervention phase, the pharmacists deve-
loped the medical history research, and subsequently they 
discussed with the responsible physicians. Then, every 
case was discussed in a clinical meeting with the multidis-
ciplinary team and, lastly, the conduction to be followed 
by the patient was presented to him by the pharmacists, 
verbally and in writing, as well as to the responsible 
physician, who usually was in charge of highlight the im-
portance of pharmacotherapeutic follow-up to the patient, 
including as a note into patient’s history, the development 
of pharmaceutical care.
After six months from the intervention phase, it was 
determined the result obtained for the resolution of the 
detected health problem, and formulated a new situation 
status, where the changes occurred in the health problems 
and pharmacological treatment after the intervention, were 
analyzed. Again, the patient was evaluated by scales of 
depression and mania.
RESULTS AND DISCUSSION
The patients with BMD are normally polymedicated 
(Zarate, Quiroz, 2003; Gazalle et al., 2007) and use, as an 
average, 6.3 ±2.9 medications, being 2.6 ±0.8 psychiatric 
(Table I). Along the study, after the first interview, a loss 
has occurred, due to patient’s death. This patient was be-
arer of Acquired Immunodeficiency Syndrome (AIDS), 
in severe condition, associated to a picture of bacterial 
pneumonia.
Only four patients (1.4%) presented DRP (Table II), 
being all of them resolved along the study. Between these 
four patients, three had problems of drug interaction, out 
of which two patients utilized medication for treatment of 
hypothyroidism joined to food. These occurrences were 
classified as DRP of effectiveness. The other patient pre-
sented an interaction between the antibiotic norfloxacin 
and lithium, being classified as a DRP of safety. After 
the oral and in writing interventions, it was observed the 
problem resolution at the pharmaceutical care of the new 
situation status.
A patient has not adapted himself to medication 
undesired effects, presenting a strong gastric illness with 
carbamazepine; so the medical team was contacted and a 
subsequent alteration of mood stabilizer prescription to li-
thium associated to valproate was done. In this case, it was 
observed a DRP linked to medication safety, which was 
already resolved at the moment of the new situation status.
The low frequency of DRP could be explained by 
the fact that these patients had constant follow-up from the 
health team; being also observed that the individuals did 
not present use of unnecessary medications. It was also 
observed that nine (32.1%) evaluated patients presented 
problems related to low adherence to treatment, which 
could result in DRP, and between the motives for this low 
adherence, the following were reported: fear of undesired 
effects, the fact that the patient was feeling well, and a 
“pause for intake of alcohol”. These individuals were ad-
vised to change their conduct, in order to prevent probable 
DRP related to low adherence.
Between the patients with problems of adherence 
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eight followed-up patients had already passed by, at least, 
one psychiatric internment, being that during the follow-
up only one patient (3.6%) was hospitalized, presenting 
as cause the maniac status (YMRS≥7). Eleven followed-
up patients (39.3%) had already attempted, at least once, 
suicide; and during the follow-up no patient had a suicide 
attempt.
Figure 1 presents the clinical comorbidities exhi-
bited by studied patients, where the most commonly ob-
served ones were: hypertension (50%), obesity (46.4%), 
hypothyroidism (39.3%), and gastric problems (32.1%). 
It is known that bipolar patients are more susceptible to 
clinical comorbidities (Angst et al., 2000) and many of 
these could be due to utilized medications, such as hypo-
thyroidism (Bocchetta et al., 2007) and obesity (Ketter, 
Haupt, 2006; Garcia-Portilla et al., 2008). It is also known 
that lithium and valproate could lead to hypothyroidism, 
and that mood stabilizers and antipsychotics could lead 
to obesity. Besides these variables, there are several other 
factors; it is known that BMD is associated to an increase 
of morbimortality for general clinical conditions, such as 
cardiovascular diseases, obesity, metabolic syndrome, dia-
betes, dyslipidemia, hypertension, inflammatory diseases 
and age, between other contributing for these outcomes 
(Cunha et al., 2008).
CONCLUSIONS
The pharmacist participates actively of the improve-
ment process of BMD patient, in a multi-professional team, 
dividing and changing information with all involved pro-
fessionals. It is possible to observe, by the DRP resolution, 
the importance of pharmacotherapeutic follow-up for the 
improvement of patient’s health. It is fundamental that he-
TABLE I – More utilized medications
*Drugs n (%)
acetylsalicylic acid 07 (25)
valproic acid or derivatives 12 (42.9)
Non-steroidal anti-inflammatory drugs 02 (7.1)
amlodipine 01 (3.6)
atenolol 01 (3.6)
biperidene 03 (10.7)
Sympathomimetic bronchodilators 03 (10.7)
bupropion 02 (7.1)
carbamazepine 06 (21.4)
lithium carbonate 19 (67.9)
carisoprodol 02 (7.1)
cimetidine 01 (3.6)
citalopram 01 (3.6)
claritidine 01 (3.6)
clonazepam 05 (17.9)
clozapine 01 (3.6)
corticoids 03 (10.7)
tiazidic diuretics 07 (25)
doxasozine 01 (3.6)
phenothiazines 12 (42.9)
fluoxetine 03 (10.7)
haloperidol 01 (3.6)
Angiotensin-Converting Enzyme Inhibitors 07 (25)
insulin 01 (3.6)
ipratropium 01 (3.6)
lamotrigine 01 (3.6)
levothyroxine 11 (39.3)
metformin 05 (17.9)
olanzapine 02 (7.1)
omeprazol 04 (14.3)
paracetamol 15 (53.6)
propranolol 05 (17.9)
risperidone 05 (17.9)
sulpiride 02 (7.1)
topiramate 01 (3.6)
valsartan 01 (3.6)
vastatins 04 (14.3)
* Multiple responses
FIGURE 1 - Frequency of clinical comorbidities.to treatment, five (55.6%) passed to have good adherence 
after the pharmacotherapeutic follow-up. On occasion 
of the first evaluation, eighteen (64.3%) patients were 
euthymic (scores lower than 7 in the scales HAM-D and 
YMRS) and the remaining ones were depressed (scores 
equal or higher than 7 in the scale HAM-D), and at the end 
of follow-up, sixteen (57.1%) patients were in euthymia, 
being that these patients who suffered mood alterations 
during the follow-up were between those with unresolved 
adherence problems. Fifteen (53.6%) between the twenty 
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alth professionals working directly with psychiatric patients 
become conscious about the importance of the orientation 
respecting the disease, the medications and all other forms 
of prescribed treatments, to be given to patients and their 
relatives. New studies, with higher number of patients and 
longer duration, are necessary to evaluate the percent of 
patients that could be effectively benefited by PC.
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